TrialEuropean journal of neurology2025

Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.

Tuan H Vu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.